Regeneron Pharmaceuticals (REGN) Treasury Shares (2011 - 2026)

Regeneron Pharmaceuticals' Treasury Shares history runs 13 years deep, the most recent figure standing at $20.6 billion for Q2 2026.

• In Q2 2026, Treasury Shares rose 19.04% year-over-year to $20.6 billion; the TTM figure through Jun 2026 stood at $20.6 billion (up 19.04% YoY), while the FY2025 annual figure was $18.6 billion, up 22.72% from the prior year.
• Treasury Shares for Q2 2026 stood at $20.6 billion, up from $19.4 billion in the prior quarter.
• The five-year high for Treasury Shares was $36.4 million in Q2 2026, with the low at $19.9 million in Q1 2022.
• The 5-year median for Treasury Shares is $26.1 million (2024), against an average of $27.2 million.
• The sharpest annual moves came in 2022 and 2024: Treasury Shares soared 33.79% in 2022, then climbed 14.36% in 2024.
• Regeneron Pharmaceuticals' Treasury Shares stood at $10.4 billion in 2022, then increased by 21.32% to $12.6 billion in 2023, then advanced by 20.76% to $15.2 billion in 2024, then gained by 22.72% to $18.6 billion in 2025, then advanced by 10.54% to $20.6 billion in 2026.
• Business Quant data shows REGN's Treasury Shares at $20.6 billion in Q2 2026, $19.4 billion in Q1 2026, and $18.6 billion in Q4 2025.